tazarotene has been researched along with Dermatitis in 2 studies
tazarotene: a topical acetylenic retinoid; a topical kerytolytic
tazarotene : The ethyl ester of tazarotenic acid. A prodrug for tazarotenic acid, it is used for the treatment of psoriasis, acne, and sun-damaged skin.
Dermatitis: Any inflammation of the skin.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sugarman, JL | 1 |
| Weiss, J | 1 |
| Tanghetti, EA | 1 |
| Bagel, J | 1 |
| Yamauchi, PS | 1 |
| Stein Gold, L | 1 |
| Lin, T | 1 |
| Martin, G | 1 |
| Pillai, R | 1 |
| Israel, R | 1 |
| Resnik, KS | 1 |
| Kutzner, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Investigator-Initiated, Open Label Trial of a Combination of Halobetasol Propionate 0.01% Andtazarotene 0.045% Lotion (Duobrii®) for Plaque Type Psoriasis of the Hands and/or Feet[NCT04720105] | Phase 4 | 22 participants (Actual) | Interventional | 2020-11-19 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Patient-reported outcomes evaluated by Dermatology Quality of Life Index (DLQI). DLQi is a 10-item questionnaire, each question is scored from 0 to 3, giving a possible score range from 0 (meaning no impact of skin disease on quality of life) to 30 (meaning maximum impact on quality of life). Higher score indicates poorer health outcome. (NCT04720105)
Timeframe: Baseline and Week 24
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Week 24 | |
| Participants With Plaque Type Psoriasis | 6.24 | 4.94 |
Treatment satisfaction evaluated by a Numerical Rating Scale (NRS). Full scale from 0 to 10, higher score indicates poorer health outcome. (NCT04720105)
Timeframe: Baseline and Week 24
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Week 24 | |
| Participants With Plaque Type Psoriasis | 1.35 | 1.29 |
Number of participants achieving Palmoplantar Physician Global Assessment (ppPGA) of 0 (clear) or 1 (almost clear/minimal) after 24 weeks of treatment. The ppPGA is based on the Investigators Global Assessment (IGA) modified version 11, specifically applied to the hands and/or feet: 0 (clear), 1 (almost clear/minimal), 2 (mild), 3 (moderate), 4 (marked/moderate-to-severe), 5 (severe) (NCT04720105)
Timeframe: Baseline and Week 24
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Week 24 | |
| Participants With Plaque Type Psoriasis | 3.47 | 2.24 |
1 review available for tazarotene and Dermatitis
| Article | Year |
|---|---|
Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 Studies.
Topics: Clinical Trials, Phase III as Topic; Clobetasol; Dermatitis; Dermatologic Agents; Drug Combinations; | 2018 |
1 other study available for tazarotene and Dermatitis
| Article | Year |
|---|---|
Mimicry illuminating pitfalls in histopathologic diagnosis: nutritional deficiency-like dermatitis secondary to topical tazarotene and keratoacanthomatous pseudocarcinomatous hyperplasia in CD30+ lymphoproliferative disorder as illustrative.
Topics: Adolescent; Child; Dermatitis; Dermatologic Agents; Diagnosis, Differential; Female; Humans; Hyperpl | 2009 |